Home/Pipeline/Eolo40 NCE

Eolo40 NCE

ALS

DiscoveryActive

Key Facts

Indication

ALS

Phase

Discovery

Status

Active

Company

Eolo Pharma

About Eolo Pharma

Eolo Pharma is developing first-in-class oral thermogenic drugs that work by increasing resting energy expenditure, a novel mechanism distinct from current appetite-suppressing treatments. Its lead program, SANA/MVD-1, is positioned as a potential monotherapy or combination agent for obesity and its comorbidities, backed by peer-reviewed research published in journals like Nature Metabolism. The company is privately held, has a pipeline of 60 novel chemical entities, and is led by a team with expertise in metabolic science and drug development. Eolo's strategy targets the massive obesity market by offering a scientifically differentiated approach to reset metabolic health.

View full company profile

Therapeutic Areas

Obesity Metabolic Disease Type 2 Diabetes NASH Hypertension ALS Alzheimer's Disease

Other ALS Drugs

Drug	Company	Phase	Status
Stem Cell Program	BioArctic	Research	Active
New targets program	Treeway	Preclinical	Active
SYF2 Program	AcuraStem	Discovery	Active
Target-03	Verge Genomics	Discovery	Active
Target-04	Verge Genomics	Discovery	Active
BIIB105 (ATXN2 ASO)	Biogen	Phase 2	Active
Undisclosed Program	bioarctic-ab	Discovery	Research